Orexo Restructures Management, Appoints Lisa Moore
Analysis based on 8 articles · First reported Mar 06, 2026 · Last updated Mar 06, 2026
The market impact for Orexo is generally positive as the company is restructuring to focus on its pipeline and Orexo===AmorphOX technology, which could lead to future growth. The departure of Robert DeLuca is a notable change, but the appointment of Lisa Moore is expected to drive product vision.
Orexo AB announced significant changes to its organizational structure and management team, effective March 6, 2026. These changes follow the divestment of Orexo===Buprenorphine/naloxone in the US market and are aimed at sharpening Orexo's focus on advancing its development programs and leveraging its Orexo===AmorphOX technology. Lisa Moore, previously part of Orexo's US leadership, has been appointed Senior Vice President, Products and Portfolio Strategy, responsible for long-term product vision and portfolio alignment with customer needs. Robert DeLuca, President of Orexo US Inc. since 2013, will retire from his role in May 2026 but will continue to support the company in an advisory capacity, particularly with the transition of Orexo===Buprenorphine/naloxone US to Dexcel Pharma USA. CEO Nikolaj Sørensen expressed gratitude for Robert DeLuca's contributions and highlighted the company's new chapter focused on pipeline advancement and strategic partnerships.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard